Shaanxi Cuikang Pharmaceutical Technology Co., Ltd

Sorafenib is a multi-kinase inhibitor. Preclinical studies have shown that sorafenib can simultaneously inhibit a variety of kinases present in cells and cell surfaces, including RAF kinase, vascular endothelial growth factor receptor-2 (VEGF-2), vascular endothelial growth factor receptor-3 (VEGF-3), and platelet-derived growth factor receptor- β (PDGFR- β)、 KIT and FLT-3. It can be seen that sorafenib has dual anti-tumor effects. On the one hand, it can directly inhibit tumor growth by inhibiting RAF/MEK/ERK signal transduction pathway; On the other hand, it can block the formation of tumor neovascularization by inhibiting VEGFR and PDGFR, and indirectly inhibit the growth of tumor cells.